106 related articles for article (PubMed ID: 23267988)
1. [Analysis of combination chemotherapy with docetaxel and nedaplatin for esophageal cancer].
Kawada J; Iwase K; Deguchi K; Higashi S; Deguchi T; Matsuda C; Tamagawa H; Omori K; Nishikawa K; Nomura M; Takagi M; Fukui A; Tanaka Y
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2095-7. PubMed ID: 23267988
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of combination chemotherapy with docetaxel and nedaplatin in patients with advanced or recurrent esophageal cancer].
Funaki H; Miura S; Morioka E; Kaida D; Ohnishi T; Ohno Y; Tomita Y; Noguchi M; Fujita H; Kinami S; Nakano Y; Ueda N; Kosaka T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2384-6. PubMed ID: 25731531
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer].
Irino T; Egawa T; Kenmochi T; Ito Y; Mihara K; Okamura A; Eto E; Inaba Y; Murakawa M; Nagashima A
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2401-4. PubMed ID: 22202395
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
Kanekiyo S; Takeda S; Nakajima M; Nishiyama M; Kitahara M; Shindou Y; Michihisa I; Abe T; Yoshino S; Hazama S; Nagano H
Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
[TBL] [Abstract][Full Text] [Related]
5. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
[TBL] [Abstract][Full Text] [Related]
6. A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma.
Matsumoto H; Hirabayashi Y; Kubota H; Murakami H; Higashida M; Haruma K; Hiratsuka J; Nakamura M; Hirai T
Anticancer Res; 2012 May; 32(5):1827-31. PubMed ID: 22593469
[TBL] [Abstract][Full Text] [Related]
7. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
Nakajima Y; Suzuki T; Haruki S; Ogiya K; Kawada K; Nishikage T; Nagai K; Kawano T
Hepatogastroenterology; 2008; 55(86-87):1631-5. PubMed ID: 19102357
[TBL] [Abstract][Full Text] [Related]
8. [A feasible study of docetaxel/nedaplatin combined chemotherapy for relapsed or refractory esophageal cancer patients as a 2nd-line chemotherapy].
Matsumoto H; Hirai T; Hirabayashi Y; Murakami H; Higashida M; Kawabe Y; Urakami A; Yamashita K; Tsunoda T
Gan To Kagaku Ryoho; 2007 May; 34(5):725-8. PubMed ID: 17496445
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Fujita Y; Hiramatsu M; Kawai M; Sumiyoshi K; Nishimura H; Tanigawa N
Dis Esophagus; 2008; 21(6):496-501. PubMed ID: 18840134
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.
Osaka Y; Takagi Y; Hoshino S; Tachibana S; Tsuchida A; Aoki T
Dis Esophagus; 2006; 19(6):473-6. PubMed ID: 17069591
[TBL] [Abstract][Full Text] [Related]
11. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
Akutsu Y; Shuto K; Kono T; Uesato M; Hoshino I; Shiratori T; Miyazawa Y; Isozaki Y; Akanuma N; Matsubara H
Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
Yamazaki K; Hironaka S; Boku N; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Hasuike N; Inui T; Yamaguchi Y; Ono H
Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer.
Kanai M; Matsumoto S; Nishimura T; Shimada Y; Watanabe G; Kitano T; Misawa A; Ishiguro H; Yoshikawa K; Yanagihara K; Teramukai S; Mitsumori M; Chiba T; Sakai Y; Fukushima M
Int J Clin Oncol; 2007 Jun; 12(3):224-7. PubMed ID: 17566847
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H
Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):853-7. PubMed ID: 23306309
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
Ueda S; Kawakami H; Nishina S; Sakiyama T; Nonagase Y; Okabe T; Tamura T; Nakagawa K
Cancer Chemother Pharmacol; 2015 Aug; 76(2):279-85. PubMed ID: 26050210
[TBL] [Abstract][Full Text] [Related]
17. [A case of advanced esophageal cancer with no recurrence treated biweekly with postoperative docetaxel/nedaplatin combined chemotherapy after non-curative surgery].
Sugimoto K; Sasaki K; Karaki H; Okaya T; Suzuki H; Hayashi S; Yamamoto K; Yamamori H; Sugano I
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1101-3. PubMed ID: 20567116
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma.
Kurita H; Yamamoto E; Nozaki S; Wada S; Furuta I; Miyata M; Kurashina K
Cancer Chemother Pharmacol; 2010 Feb; 65(3):503-8. PubMed ID: 19579024
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of docetaxel and nedaplatin combined with concurrent intensity modulated radiation therapy in the treatment of esophageal cancer].
Bi LW; Zhang LZ; Zhao HF
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):710-1. PubMed ID: 23159088
[No Abstract] [Full Text] [Related]
20. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Tanaka T; Fujita H; Sueyoshi S; Tanaka Y; Sasahara H; Mori N; Nagano T; Yamana H; Shirouzu K
Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
